GENERIC DRUG FIRMS NEED TO LOOK INTO COST-EFFECTIVENESS STUDIES TO STAY COMPETITIVE WITH BRANDNAME FIRMS IN MANAGED CARE ERA, MCKESSON VP TELLS NAPM
Manufacturers and marketers of generic pharmaceuticals should consider cost-effectiveness studies as one means of keeping pace competitively with brandname drug companies, McKesson Drug VP- Professional Services Robert Abrams indicated Jan. 19 at the National Association of Pharmaceutical Manufacturers' annual meeting in Dorado, Puerto Rico.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth